Safety of an extended-release injectable 10% moxidectin suspension
The safety of an extended-release injectable suspension of 10% moxidectin was evaluated in four studies using Beagle dogs and one study using ivermectin-sensitive Collies at a recommended dose is 0.5 mg/kg subcutaneously once yearly.
RESULTS:
In study 1: slight swelling was detectable at some of the 3 and 5 times recommended dose.
Studies 2 and 3 showed no ill effects identified in reproductive (females) or semen quality characteristics (males).
Study 4: Showed no adverse effects.
Study 5: there were no abnormal clinical signs at the recommended dose and also at 3 and 5 times the recommended dose in ivermectin-sensitive dogs.
Read more by clicking on the link below:
Safety of an extended-release injectable moxidectin suspension formulation in dogs.
Share This Article
Free Membership
Enjoyed this article?
There's a lot more where that came from.
Join 50,000+ veterinary professionals who get free RACE-approved CE, weekly clinical updates, and the most talked-about veterinary magazine in the profession — all completely free.
Join Vet Candy Free →No credit card. No catch. Just everything veterinary.